Jordyn Sava


Mortality Rates Across Leading Types of Cancer Vary Globally

A study looking at mortality rates from major cancer types may help inform cancer prevention and treatment strategies, and lead to a reduction to the global cancer disparities seen today.

John Nakayama, MD


Discussing Recent Advances for Patients With Endometrial Cancer

John Nakayama, MD, discusses what the evolution of endometrial cancer treatment has looked like in recent years.

Yazan Samhouri, MD


Significance of the TRIANGLE Study of Frontline Ibrutinib for MCL

Yazan Samhouri, MD, discusses his impressions of the TRIANGLE clinical trial presented at the 2022 American Society of Hematology Annual Meeting.

Jared Kaltwasser


Many Challenges, Opportunities for CAR T-Cell Therapies in Lymphoma

Sattva S. Neelapu, MD will discuss chimeric antigen receptor T-cell therapy will in lymphoma iduring a session at the SOHO 2022 Annual Meeting.

Krina K. Patel, MD, MSc


Unmet Needs in R/R MM and Clinical Practice Pearls

Closing their discussion, the panel highlights unmet needs in the management of relapsed/refractory multiple myeloma and shares clinical pearls for community physicians.

Chandler H. Park, MD


Recent Trial Updates in Advanced Renal Cell Carcinoma (RCC)

In the second article of this series, Chandler H. Park, MD, a genitourinary oncologist at Norton Cancer Institute, reviews recently updated data on advanced renal cell carcinoma treatments.

Catherine C. Coombs, MD


Unmet Needs and Clinical Pearls for Treating Relapsed/Refractory CLL

Catherine C. Coombs, MD, discusses unmet needs and offers advice for community oncologists treating patients with relapsed/refractory chronic lymphocytic leukemia.

Rogerio C. Lilenbaum, MD


Molecular Testing Used for Patients With Non-Small Cell Lung Cancer

Rogerio C. Lilenbaum, MD, discusses molecular panels and other testing for patients with nonsquamous non-small cell lung cancer.

Paul Boutros, PhD, MBA


Exploring the Reasons Why Certain Prostate Cancers Are More Aggressive

Paul Boutros, PhD, MBA, discusses the reasons why some patients with prostate cancer have more aggressive disease than others.

S. Michelle Shiller, DO, AP/CP, MGP


Looking Towards the Future of Molecular Testing and Additional Treatment Options for Patients with mNSCLC

The panel closes by summarizing recent advances in the field and shares hopes for future improvements in molecular testing and treatment options for patients with mNSCLC.

Radhika Takiar, MD


The Role of Targeted Therapies in Frontline Treatment of Mantle Cell Lymphoma

There have been marked improvements in expected remission and overall survival rates in mantle cell lymphoma even though a cure for this disease remains elusive.

Naomi Haas, MD


Factors Influencing Frontline Therapy Options for Favorable-Risk RCC

Naomi B. Haas, MD, discusses the choice of frontline treatment for favorable-risk patients with advanced clear cell renal cell carcinoma.

Janna Afanasjeva, PharmD, BCPS


Improved Sensitivity, Monitoring Needed for MRD in Adult and Pediatric ALL

Despite advances with MRD monitoring, further research and practice advances are needed to continue the trend for improving outcomes in patients with acute lymphoblastic leukemia.

Jimmy Caudell, MD, PhD


Varying Incidence of HPV-Positive and Negative Oropharyngeal Cancers

Jimmy Caudell, MD, PhD, discusses the overall incidence of human papillomavirus-positive and negative oropharyngeal cancers in the United States.

Jalal S. Baig, MD


Multiple Factors at Play in the Rise of Early-Onset Colorectal Cancer

Oncologists are seeing early onset colorectal cancer more frequently, according to Jalal S. Baig, MD.

Enrique Soto Pérez de Celis, MD, MSc


Older Patients With Triple-Negative Breast Cancer Should Be Assessed Different for Treatment

Enrique Soto Pérez de Celis, MD, MSc, explains that although geriatric patients with breast cancer can be treated similarly to their younger counterparts, more steps are involved in the treatment decision-making process, starting with appropriate assessment of the patient.

Scott R. Goldsmith, MD


In Multiple Myeloma, Will ASCT Survive Collision With CAR T-Cell Therapy?

With two recently approved chimeric antigen receptor T therapies targeting B-cell maturation antigen, this novel platform has altered the treatment paradigm for heavily-pretreated patients with multiple myeloma.

Kevin Wright


Promising Results Seen With Pembrolizumab Plus Chemoradiation in Stage III NSCLC

Antitumor activity was seen in the combination of pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer, regardless of PD-L1 status or tumor histology.

Luv N. Hajirawala, MD


Combined Risk Factors Lead to Worse Outcomes in Colon Cancer

Luv N. Hajirawala, MD, discusses the findings from a retrospective analysis of the Surveillance, Epidemiology and End Results database looking at patients with stage III colon cancer.

Chad Tang, MD


Current Therapies & Ongoing Research in the Prostate Cancer Space

Chad Tang, MD, discusses currently available treatment options and recent research in the prostate cancer space.

Taymeyah Al-Toubah, MPH


Using Capecitabine/Temozolomide or 177Lu-Dotatate to Treat NETs Requires Real-World Guide

A real-world guide to best practices in treating neuroendocrine tumors can improve patient outcomes.

Jamie Cesanek


Second-Line Regorafenib/Nivolumab Is Deemed Safe for HCC

For patients with hepatocellular carcinoma treated in the second-line setting, the combination of regorafenib and nivolumab following 2 cycles of regorafenib monotherapy appeared safe, according to phase 1/2a study.

Mahvish Muzaffar MD


Liver Cancer Awareness Month: A Decade of Progress and Hope in Hepatocellular Carcinoma

Mahvish Muzaffar, MD, and Nasreen Vohra, MD, from the Brody School of Medicine/East Carolina University, discuss the past decade of progress in treatment for patients with hepatocellular carcinoma.

Terry P. Mamounas, MD, MPH


Exploring Adjuvant Endocrine Therapy in the Breast Cancer Setting

Terry P. Mamounas, MD, MPH, discusses the use of extended adjuvant therapy for patients with breast cancer and how the landscape is evolving.

Joseph M. Curry, MD


Immune Checkpoint Inhibitors Offer New Approaches in Head and Neck Cancer

Joseph M. Curry, MD, discusses the introduction of immune checkpoint inhibitors for the treatment of patients with head and neck cancers.

Margarett C. Ellison, MD, MHA, FACS, FACOG


Cervical Cancer Awareness Month: Trials Assess New Immunotherapies

Margarett C. Ellison, MD, MHA, FACS, FACOG, gynecologic oncologist for Gynecologic Oncology of Tallahassee, a Division of Florida Cancer Specialists & Research Institute, reviews potential immunotherapy treatments for Cervical Cancer Awareness Month.

Carole Miller


Factors Correlating With Survival in Polycythemia Vera

Carole Miller, MD, discusses notable factors which correlated with survival for patients with polycythemia vera in the REVEAL study.

Christopher E. Touloukian, MD


Post–COVID-19 Infection Remains a Concern in Patients With Cancer

Many questions remain unanswered about COVID-19, and we are now experiencing another problem—postacute sequelae of SARS-CoV-2 infection, also referred to as post–COVID-19 condition or post-COVID syndrome.

Tapan Kadia, MD


Recently Introduced Low-Intensity Options for Older Patients With AML

Tapan Kadia, MD, discusses the recent and upcoming changes in treatment of acute myeloid leukemia for patients who are not candidates for intensive remission induction therapy.